Publications
原著論文
2024年
- Factors Influencing Serum Posaconazole Concentrations in Patients with Hematologic Malignancies Receiving Delayed-Release Tablets.
Yamada T*, Belabbas T, Suetsugu K, Hirota T, Mori Y, Kato K, Akashi K, Egashira N, Ieiri I.
Ther Drug Monit. 2024 Apr 4. doi: 10.1097/FTD.0000000000001196. Online ahead of print
(*corresponding author)
2023年
- Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.
Belabbas T, Yamada T, Egashira N, Hirota T, Suetsugu K, Mori Y, Kato K, Akashi K, Ieiri I.
J Infect Chemother. 2023 Apr;29(4):391-400. doi: 10.1016/j.jiac.2023.01.010. - Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes.
Matsukane R, Suetsugu K, Hata K, Matsuda K, Nakao S, Minami H, Watanabe H, Hirota T, Egashira N, Ieiri I.
Int J Clin Oncol. 2023 May 11. doi: 10.1007/s10147-023-02349-3.
- Identification of a New Pyrrolyl Pyridoindole Alkaloid, Melpyrrole, and Flazin from Honey and Their Cough-Suppressing Effect in Guinea Pigs
Tani H, Yamaga M, Sekiya T, Isohama Y, Koshino H, Nogawa T, Yamaki A, Takahashi S.
J. Agric. Food Chem. 2023, 71, 37, 13805–13813. DOI: 10.1021/acs.jafc.3c03864
2022年
- Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis.
Yamada T*, Soda M, Nishida R, Miyake N, Maeshiro Y, Oida Y, Yamashita Y, Egashira N, Shimono N, Kitaichi K, Ieiri I.
Drug Metab Pharmacokinet. 2022 Jun;44:100444. doi: 10.1016/j.dmpk.2022.100444. Epub 2022 Jan 7.
(*corresponding author) - Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
Yamada T*, Emoto C, Fukuda T, Motomura Y, Inoue H, Ohga S, Ieiri I.
Ther Drug Monit. 2022 Jun 1;44(3):404-413. doi: 10.1097/FTD.0000000000000930.(*corresponding author)
Patsalos Prize (Best TDM manuscript published in Therapeutic Drug Monitoring 2021-2022) 受賞論文 - Development of Versatile and Interactive Model Lessons in Kampo Medicine Education.
Kainuma M, Kikukawa M, Egashira N, Morimoto S, Miyata J, Shimazoe T.
Tokai J Exp Clin Med. 2022 Dec 20;47(4):154-161. - Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity.
Zhang W, Matsukane R, Egashira N, Tsuchiya Y, Fu R, Yamamoto S, Hirota T, Ieiri I.
Toxicol Appl Pharmacol. 2022 Aug 15;449:116112. doi: 10.1016/j.taap.2022.116112. - The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats.
Shigematsu T, Tajima S, Fu R, Zhang M, Itoyama Y, Tsuchimoto A, Egashira N, Ieiri I.
Life Sci. 2022 Jan 1;288:120150. doi: 10.1016/j.lfs.2021.120150.
2021年
- Kamishoyosan potentiates pentobarbital-induced sleep in socially isolated, ovariectomized mice.
Egashira N*, Goto Y, Iba H, Kawanaka R, Takahashi R, Taniguchi C, Watanabe T, Kubota K, Katsurabayashi S, Iwasaki K.
J Ethnopharmacol. 2021 Dec 5;281:114585. doi: 10.1016/j.jep.2021.114585.
(*corresponding author) - Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats.
Egashira N*, Goto Y, Takahashi R, Iba H, Yamamoto S, Watanabe T, Kubota K, Kawashiri T, Taniguchi C, Katsurabayashi S, Iwasaki K.
J Pharmacol Sci. 2021 Sep;147(1):114-117. doi: 10.1016/j.jphs.2021.06.004.
(*corresponding author) - Development and Full Validation of a Bioanalytical Method for Quantifying Letermovir in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry.
Belabbas T, Yamada T, Tsuchiya Y, Suetsugu K, Egashira N, Ieiri I.
Chem Pharm Bull (Tokyo). 2021;69(7):646-651. doi: 10.1248/cpb.c21-00142. - Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.
Emoto C, Johnson TN, Yamada T, Yamazaki H, Fukuda T.
Eur J Clin Pharmacol. 2021 Aug;77(8):1157-1168. doi: 10.1007/s00228-021-03098-w. - Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events.
Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N*.
Sci Rep. 2021 Jan 14;11(1):1324. doi: 10.1038/s41598-020-79397-6.
(*corresponding author) - Analgesic Effects of Sokeikakketsuto on Chemotherapy-Induced Mechanical Allodynia and Cold Hyperalgesia in Rats.
Nakamura H, Kawashiri T, Kobayashi D, Uchida M, Egashira N, Shimazoe T.
Biol Pharm Bull. 2021;44(2):271-274. doi: 10.1248/bpb.b20-00620.
総説
2021年
- Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy.
Egashira N*.
Front Pain Res (Lausanne). 2021 Dec 8;2:804260. doi: 10.3389/fpain.2021.804260.
(*corresponding author) - Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy.
Yamamoto S, Egashira N*.
Front Pharmacol. 2021 Jan 14;11:607780. doi: 10.3389/fphar.2020.607780.
(*corresponding author) - Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Yamamoto S, Egashira N*.
Int J Mol Sci. 2021 Jan 17;22(2):888. doi: 10.3390/ijms22020888.
(*corresponding author) - Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence.
Kawashiri T, Mine K, Kobayashi D, Inoue M, Ushio S, Uchida M, Egashira N, Shimazoe T.
Int J Mol Sci. 2021 Jan 30;22(3):1393. doi: 10.3390/ijms22031393. - Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy.
Kawashiri T, Inoue M, Mori K, Kobayashi D, Mine K, Ushio S, Kudamatsu H, Uchida M, Egashira N, Shimazoe T.
Int J Mol Sci. 2021 Aug 13;22(16):8733. doi: 10.3390/ijms22168733.
講演・シンポジウム
2024年
- ベーシックセミナー：新人薬剤師が知っておきたいTDMの基礎知識
山田孝明
第45回日本病院薬剤師会近畿学術大会, 2024年1月27日, 和歌山
2023年
- シンポジウム：小児薬物療法におけるファーマコメトリクスの利活用 -臨床薬剤師の視点から-
山田孝明
第39回日本TDM学会・学術大会, 2023年6月24日, 京都
- 特別講演：抗菌薬・抗真菌薬の投与量適正化を目指した取り組み
山田孝明
第23回福岡感染症適正治療研究会, 2023年9月9日, 福岡
2022年
- シンポジウム：小児薬物療法の基礎知識と留意点
山田孝明
第32回日本医療薬学会年会, 2022年9月25日, 群馬
2021年
- シンポジウム：ダプトマイシンのPK/PDとTDM
山田孝明
第48回日本集中治療医学会学術集会, 2021年2月12日, Web講演 - シンポジウム：小児臨床薬理学入門 -臨床薬理学に基づいた小児薬用量の考え方-
山田孝明
第17回日本血管腫血管奇形学会学術集会, 2021年10月2日, Web講演
競争的資金
2024年
- 薬剤性間質性肺炎のバイオマーカーの探索ならびに新規予防法の開発
基盤研究(C) 2024–2027
江頭伸昭（研究代表者）
2022年
- 小児・新生児における数理学的モデルを用いた抗菌薬個別化投与の新展開
基盤研究(C) 2022-2025
山田孝明（研究代表者）
2021年
- 生体膜リン脂質に着目した抗がん薬誘発末梢神経障害予防/治療薬の開発
基盤研究(C) 2021-2023
江頭伸昭（研究代表者）
著書
2022年
- 薬剤師のための薬物療法問題集
山田孝明（共同執筆）
じほう 2022年9月 (ISBN: 9784840754620)
2020年以前の業績は、research mapをご参照下さい。
江頭伸昭：https://researchmap.jp/read0213408
山田孝明：https://researchmap.jp/tyamada-1981